Selected article for: "acute respiratory syndrome coronavirus and low quality evidence"
Author: Meini, Simone; Pagotto, Alberto; Longo, Benedetta; Vendramin, Igor; Pecori, Davide; Tascini, Carlo
Title: Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives
  • Cord-id: 4x9anilx
  • Document date: 2020_6_30
    • ID: 4x9anilx
    Snippet: A life-threatening respiratory illness (COVID-19) due to severe acute respiratory syndrome (SARS)-CoV-2 coronavirus was first described in December 2019 in Wuhan (China), rapidly evolving into a pandemic. In the first phase, when the viral replication plays a pivotal pathogenetic role, antiviral drugs could be crucial in limiting viral-induced organ damage. Unfortunately, there are no specific antivirals of proven efficacy for COVID-19, and several drugs have been repurposed to face this dramati
    Document: A life-threatening respiratory illness (COVID-19) due to severe acute respiratory syndrome (SARS)-CoV-2 coronavirus was first described in December 2019 in Wuhan (China), rapidly evolving into a pandemic. In the first phase, when the viral replication plays a pivotal pathogenetic role, antiviral drugs could be crucial in limiting viral-induced organ damage. Unfortunately, there are no specific antivirals of proven efficacy for COVID-19, and several drugs have been repurposed to face this dramatic pandemic. In this paper we review the studies evaluating lopinavir/ritonavir association (LPV/r) use in COVID-19, and previously in SARS and Middle East respiratory syndrome (MERS). We searched PubMed to identify all relevant clinical and laboratory studies published up to 15 May 2020; the guidelines on the use of LPV/r in COVID-19 were further directly searched on the website of the main international scientific societies and agencies. Available evidence is currently scarce and of low quality. The recommendations issued for COVID-19 vary from positions clearly against the use of LPV/r to other positions that are more favorable. In our opinion, despite the controversial results of an important randomized clinical trial, and some recommendations, clinicians should not abandon the use of LPV/r for the treatment of COVID-19, possibly using this drug inside a prospective randomized trial, waiting for the results of the numerous ongoing trials evaluating its efficacy.

    Search related documents:
    Co phrase search for related documents
    • abdominal discomfort nausea and acute respiratory syndrome: 1, 2, 3, 4, 5, 6
    • abnormal liver function and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • abnormal liver function test and acute respiratory syndrome: 1, 2, 3
    • abstract title and acute ards respiratory distress syndrome: 1
    • abstract title and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • abstract title and additional information: 1, 2
    • abstract title screen and acute respiratory syndrome: 1, 2
    • accessible treatment and acute ards respiratory distress syndrome: 1, 2
    • accessible treatment and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8
    • active drug and acute ards respiratory distress syndrome: 1
    • active drug and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active site and acute ards respiratory distress syndrome: 1, 2
    • active site and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active site and additional information: 1, 2
    • acute ards respiratory distress syndrome and additional information: 1, 2, 3